AI Verdict
LEVI has stronger fundamentals based on our AI analysis.
LEXX vs LEVI Fundamental Comparison
| Metric | LEXX | LEVI |
|---|---|---|
| Revenue | $0.0 | $1.7B |
| Net Income | $-1.6M | $175.8M |
| Net Margin | N/A | 10.1% |
| ROE | -32.5% | 8.0% |
| ROA | -26.4% | 2.7% |
| Current Ratio | 3.68x | 1.58x |
| Debt/Equity | 0.00x | 0.48x |
| EPS | $-0.07 | $0.45 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LEXX vs LEVI: Frequently Asked Questions
Is LEXX or LEVI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LEVI has stronger fundamentals. LEXX is rated SELL (72% confidence) while LEVI is rated BUY (72% confidence). This is not investment advice.
How does LEXX compare to LEVI fundamentally?
Lexaria Bioscience Corp. has ROE of -32.5% vs LEVI STRAUSS & CO's 8.0%. Net margins are N/A vs 10.1% respectively.
Which stock pays higher dividends, LEXX or LEVI?
LEXX has a dividend yield of N/A or no dividend while LEVI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LEXX or LEVI for long term?
For long-term investing, consider that LEXX has SELL rating with 72% confidence, while LEVI has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LEXX vs LEVI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LEXX vs LEVI, the AI consensus favors LEVI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.